Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study’s primary objectives

Plasma concentrations within the potential therapeutic dose range were consistent with efficacious exposure levels established in nonclinical disease models and support once-daily oral dosing

Read more at globenewswire.com

Related news for (FRTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.